Which cancer types are Gosatuzumab/Todavir suitable for?

Gosatuzumab/Trodelvy (Trodelvy) is an innovative antibody-drug conjugate (ADC) that has been approved by many countries and regions for the treatment of certain types of advanced cancer. It brings new treatment opportunities to patients, especially when traditional treatments have limited efficacy or are resistant. Its mechanism of action is based on targeting the Trop-2 protein, a cell surface antigen highly expressed in a variety of solid tumors, especially triple-negative breast cancer and urothelial cancer. By linking the anti-Trop-2 antibody with the active chemotherapy ingredient SN-38, gosatuzumab can precisely release the drug to tumor cells, achieving efficient killing while reducing damage to normal tissue.

Gosatuzumab is indicated for three main cancer types. The first is in patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), who have often received two or more systemic therapies and whose disease continues to progress. Since mTNBC lacks hormone receptors and HER2 targets, its treatment options are very limited, and gosatuzumab provides a new solution for such patients through its ADC mechanism. Secondly, for patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, especially those who have received at least two systemic treatments in the metastatic stage with poor results, gosatuzumab is also listed as one of the recommended drugs for later-line treatment. Such patients often face a depletion of treatment options after experiencing failure of endocrine therapy and chemotherapy. Gosatuzumab's targeted-chemotherapy dual mechanism provides strong support for them.

In addition, gosatuzumab is also suitable for patients with locally advanced or metastatic urothelial carcinoma ( mUC), especially those adult patients who have previously received platinum-based chemotherapy and have used PD-1 or PD-L1 immune checkpoint inhibitors. In this patient population, where conventional treatment options have been largely exhausted, gosatuzumab offers new hope for survival and shows the potential to improve disease control in some populations.

Reference materials:https://www.trodelvy.com/